ZP4207 in multiple-dose pen: Phase Ib data

A double-blind, placebo-controlled, German Phase Ib trial in 24 healthy volunteers showed that once-daily doses of subcutaneous ZP4207 for 5 days were well tolerated and led to “clinically relevant” i...